Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

Researchers found that 41% of referrals within a community-based transplant and cell therapy network were unable to access timely CAR T-cell therapy for non-Hodgkin lymphoma. The main cause of ineligibility was attrition from disease-related factors, underscoring the importance of reducing time to apheresis, early referral, and attention to salvage/bridging strategies.